Founded in 2003, Marinus Pharmaceuticals is a privately held specialty pharmaceutical company located in New Haven, Connecticut. Marinus is dedicated to the reformulation, development, and commercialization of ganaxolone to treat serious neurological and psychiatric disorders. Ganaxolone is the most advanced neurosteroid in development for Epilepsy, Posttraumatic Stress Disorder and Fragile-X Syndrome. Marinus has completed a successful Phase 2 trial with ganaxolone in adult partial onset seizures, and a Phase 2 proof of concept PTSD study has initiated with the INTRuST Consortium. A study of ganaxolone for Fragile-X Syndrome in children is underway through the MIND Institute at University of California Davis. Marinus' investors include Domain Associates, Canaan Partners, RusnanoMedInvest, Sofinnova Ventures and Foundation Medical Partners.